hotspot -WSS

hotspot

author：knowledge 2025-09-30 23:06:37 - browse：16659

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

WSS

Designating disabled people as health disparity population is crucial

Stopping antidepressants leads to symptoms for 1 in 6 patients

Senators tussle over abortion against the backdrop of a presidential campaign

STAT wants to know your pick for a great summer read or listen

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

hotspot

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CMS got Medicare Advantage quality rating wrong, judge rules

In Memoriam: Notable people who died in 2023

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Bright Health sells Medicare Advantage business to Molina

New Medicare drug pricing powers could soon be upended in court

Jerome Adams on the need for new antivirals for Covid

Data don't support strong claims for Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

For pregnant people, addiction treatment shouldn't mean a call to child protective services

focus

Sutter Health’s antitrust win overturned by appeals court

Elevance PBM president out as customers face prescription chaos

DeSantis can now import cheaper drugs. But will Biden get credit?

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

The nurse manager staffing crisis is hurting patients

hotspot

explore

hotspot

explore